CMR negotiates with World Funds for a $155 million financing

Cameroun seeks to obtain a financing of 155 million USD (approximately 77,5 billion francs CFA) for the fight against the AIDS with world Funds also dedicated to this pandemic like tuberculosis and the malaria whose joint mission with the ONUSIDA paid a visit to Yaounde, according to an institutional source.

Created in 2002 with an aim of increasing the resources allocated for this cause, the world Funds for fight against the AIDS, tuberculosis and malaria laid down the objective to mobilize 15 billion USD contributions between 2013 and 2016 in order to save 5,8 million lives thanks to the treatment and to extend the prevention of these diseases in the world, particularly in Africa.

In 2014, Cameroon submitted a request for financing in forecast of the round 11 which did not receive approval for nonconformity with the new criteria of financing of the Funds and the failures in its system of prevention and fight against AIDS, according to internal sources to the national Committee of fight against the AIDS.

Within the framework of the round 10 which runs until the end of this year, it had profited in 2011 from an envelope of 64 billion francs CFA (128 million USD). Indeed, the world Funds for the fight against the AIDS, tuberculosis and malaria installed a new mechanism of bearing financing on the combination of the strategies deployed by the countries for the fight against AIDS with those related to tuberculosis, for the taking into account of the dimension of Co infection to HIV.

This mechanism prescribes a systematic tracking for any patient of tuberculosis. For Cameroon, the recommendations of the world Funds required moreover a system of transparency and traceability in management of the antiretroviral treatments (ARV), in order to suppress the illicit phenomenon of sale of these drugs to the detriment of the health of the patients.

In addition to the application of the standards of labelling, it is in addition recommended to the Cameroonian authorities to ensure a better quality control of the ARV.